JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Selected (68)Ga-siderophores versus (68)Ga-colloid and (68)Ga-citrate: biodistribution and small animal imaging in mice.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
PUBLISHED: 11-04-2014
Show Abstract
Hide Abstract
(68)Ga-triacetylfusarinine C (TAFC) and (68)Ga-ferrioxamine E (FOXE) show great potential to be used as highly sensitive and selective tracers for Aspergillus infection imaging. Here we report on a comparison of the ex vivo biodistribution and small animal imaging of (68)Ga-TAFC and (68)Ga-FOXE versus (68)Ga-colloid and (68)Ga-citrate as unspecific control in mice.
Related JoVE Video
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD).
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 08-02-2014
Show Abstract
Hide Abstract
The preparation of an Investigational Medicinal Product Dossier (IMPD) for a radiopharmaceutical to be used in a clinical trial is a challenging proposition for radiopharmaceutical scientists working in small-scale radiopharmacies. In addition to the vast quantity of information to be assembled, the structure of a standard IMPD is not well suited to the special characteristics of radiopharmaceuticals. This guideline aims to take radiopharmaceutical scientists through the practicalities of preparing an IMPD, in particular giving advice where the standard format is not suitable. Examples of generic IMPDs for three classes of radiopharmaceuticals are given: a small molecule, a kit-based diagnostic test and a therapeutic radiopharmaceutical.
Related JoVE Video
Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective.
J Labelled Comp Radiopharm
PUBLISHED: 05-29-2014
Show Abstract
Hide Abstract
This document is meant to complement Part B of the EANM 'Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals' issued by the Radiopharmacy Committee of the European Association of Nuclear Medicine, covering small-scale in-house preparation of radiopharmaceuticals with automated modules. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of radiopharmaceuticals, which are not intended for commercial purposes or distribution.
Related JoVE Video
Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinsons disease.
Brain
PUBLISHED: 09-06-2013
Show Abstract
Hide Abstract
Signal abnormalities of the substantia nigra and the olfactory tract detected either by diffusion tensor imaging, including measurements of mean diffusivity, a parameter of brain tissue integrity, and fractional anisotropy, a parameter of neuronal fibre integrity, or transcranial sonography, were recently reported in the early stages of Parkinsons disease. In this study, changes in the nigral and olfactory diffusion tensor signal, as well as nigral echogenicity, were correlated with clinical scales of motor disability, odour function and putaminal dopamine storage capacity measured with 6-[(18)F] fluorolevodopa positron emission tomography in early and advanced stages of Parkinsons disease. Diffusion tensor imaging, transcranial sonography and positron emission tomography were performed on 16 patients with Parkinsons disease (mean disease duration 3.7 ± 3.7 years, Hoehn and Yahr stage 1 to 4) and 14 age-matched healthy control subjects. Odour function was measured by the standardized Sniffin Sticks Test. Mean putaminal 6-[(18)F] fluorolevodopa influx constant, mean nigral echogenicity, mean diffusivity and fractional anisotropy values of the substantia nigra and the olfactory tract were identified by region of interest analysis. When compared with the healthy control group, the Parkinsons disease group showed significant signal changes in the caudate and putamen by 6-[(18)F] fluorolevodopa positron emission tomography, in the substantia nigra by transcranial sonography, mean diffusivity and fractional anisotropy (P < 0.001, P < 0.01, P < 0.05, respectively) and in the olfactory tract by mean diffusivity (P < 0.05). Regional mean diffusivity values of the substantia nigra and the olfactory tract correlated significantly with putaminal 6-[(18)F] fluorolevodopa uptake (r = -0.52, P < 0.05 and r = -0.71, P < 0.01). Significant correlations were also found between nigral mean diffusivity values and the Unified Parkinsons Disease Rating Scale motor score (r = -0.48, P < 0.01) and between mean putaminal 6-[(18)F] fluorolevodopa uptake and the total odour score (r = 0.58; P < 0.05) as well as the Unified Parkinsons Disease Rating Scale motor score (r = -0.53, P < 0.05). This study reports a significant association between increased mean diffusivity signal and decreased 6-[(18)F] fluorolevodopa uptake, indicating that microstructural degradation of the substantia nigra and the olfactory tract parallels progression of putaminal dopaminergic dysfunction in Parkinsons disease. Since increases in nigral mean diffusivity signal also correlated with motor dysfunction, diffusion tensor imaging may serve as a surrogate marker for disease progression in future studies of putative disease modifying therapies.
Related JoVE Video
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 05-09-2013
Show Abstract
Hide Abstract
(18)F-Fluoro-L-dihydroxyphenylalanine ((18)F-DOPA) PET offers high sensitivity and specificity in the imaging of nonmetastatic extra-adrenal paragangliomas (PGL) but lower sensitivity in metastatic or multifocal disease. These tumours are of neuroendocrine origin and can be detected by (68)Ga-DOTA-Tyr(3)-octreotide ((68)Ga-DOTA-TOC) PET. Therefore, we compared (68)Ga-DOTA-TOC and (18)F-DOPA as radiolabels for PET/CT imaging for the diagnosis and staging of extra-adrenal PGL. Combined cross-sectional imaging was the reference standard.
Related JoVE Video
Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.
Anticancer Res.
PUBLISHED: 04-09-2013
Show Abstract
Hide Abstract
Vasoactive intestinal peptide (VIP) receptors are overexpressed in a broad variety of tumours. For the detection of these tumours, novel chemically modified and shortened VIP derivatives were designed.
Related JoVE Video
??Ga-DOTA?-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 02-16-2013
Show Abstract
Hide Abstract
??Ga-labelled DOTA?-Tyr³-octreotide positron emission tomography (PET)/CT (??Ga-DOTATOC PET/CT) is a routinely used imaging modality for neuroendocrine tumours expressing somatostatin receptors (SSTRs). Recent studies have shown that SSTRs are also expressed in head and neck squamous cell carcinoma (HNSCC). This is the first prospective clinical trial investigating SSTR expression in patients with HNSCC using ??Ga-DOTATOC.
Related JoVE Video
Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.
Int J Nanomedicine
PUBLISHED: 01-01-2013
Show Abstract
Hide Abstract
The significant progress in nanotechnology provides a wide spectrum of nanosized material for various applications, including tumor targeting and molecular imaging. The aim of this study was to evaluate multifunctional liposomal nanoparticles for targeting approaches and detection of tumors using different imaging modalities. The concept of dual-targeting was tested in vitro and in vivo using liposomes derivatized with an arginine-glycine-aspartic acid (RGD) peptide binding to ?v?3 integrin receptors and a substance P peptide binding to neurokinin-1 receptors.
Related JoVE Video
[99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
Cancer Biother. Radiopharm.
PUBLISHED: 09-01-2011
Show Abstract
Hide Abstract
Neurotensin subtype 1 receptor overexpression is found in a variety of human tumors. The aim of this pilot/phase I study was to assess the safety profile, pharmacokinetics, and imaging characteristics of (99m)Tc-Demotensin VI in tumor patients.
Related JoVE Video
Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system.
Nucl Med Commun
PUBLISHED: 08-31-2011
Show Abstract
Hide Abstract
Radiolabelled somatostatin analogues have found wide clinical use in nuclear medicine for both diagnostic and therapeutic applications. Here, we describe the development of a fully automated synthesis system allowing radiolabelling of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-derivatized peptides with ??Ga/¹¹¹In/¹??Lu and ??Y, meeting radiation safety and pharmaceutical requirements.
Related JoVE Video
In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging.
Nucl. Med. Biol.
PUBLISHED: 07-28-2011
Show Abstract
Hide Abstract
Siderophores are low-molecular-mass iron chelators serving as iron transporters for almost all bacteria, fungi and some plants. Iron is an essential element for majority of organisms and plays an important role in virulence of pathogenic organisms. (68)Ga is a positron emitter with complexing properties comparable to those of Fe(III) and readily available from a generator. Initial studies with (68)Ga-triacetylfusarinine C (TAFC) showed excellent targeting properties in a rat infection model. We report here on the in vitro and in vivo evaluation of other siderophores radiolabelled with (68)Ga as potential radiopharmaceuticals for infection imaging.
Related JoVE Video
Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 04-06-2011
Show Abstract
Hide Abstract
Stability of radiolabelled cholecystokinin 2 (CCK2) receptor targeting peptides has been a major limitation in the use of such radiopharmaceuticals especially for targeted radionuclide therapy applications, e.g. for treatment of medullary thyroid carcinoma (MTC). The purpose of this study was to compare the in vitro stability of a series of peptides binding to the CCK2 receptor [selected as part of the COST Action on Targeted Radionuclide Therapy (BM0607)] and to identify major cleavage sites.
Related JoVE Video
Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.
Nanomedicine
PUBLISHED: 02-25-2011
Show Abstract
Hide Abstract
Radiolabeled PEGylated liposomal nanoparticles (NPs) open new possibilities for a variety of applications including diagnosis, drug delivery, targeted therapy, and monitoring treatment effects. Here we describe the characterization of liposomal NPs (liposomes and micelles) derivatized with the somatostatin analogue tyrosine-3-octreotide as a proof of concept for tumor targeting. NPs were radiolabeled with indium-111, and targeting properties were evaluated in vitro on rat pancreatic tumor cells (AR42J), demonstrating specific binding and IC(50) values in the low nanomolar range. Biodistribution studies were performed in Lewis rats and compared to single-photon emission computed tomography images. Moderate tumor uptake was found in xenografted nude mice (<2.5% ID/g tissue) as compared to control. Micelles and liposomes revealed comparable pharmacokinetics and targeting properties. This study provides insight into tumor-targeting characteristics of peptide-derivatized liposomal NPs and can serve as a basis for further improvement of these constructs.
Related JoVE Video
Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
Nucl. Med. Biol.
PUBLISHED: 02-15-2011
Show Abstract
Hide Abstract
Lack of correlation between in vitro and in vivo stability is a general problem for the development of radiopeptides especially in the case of minigastrin derivatives for therapeutic applications. In this study, we compared the influence of experimental conditions on radiopeptide stability results in vitro using a model Minigastrin (MG) analogue labelled with Lu-177. Additionally, we attempted to characterize the main serum enzymatic cleavage sites by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) analysis.
Related JoVE Video
[68Ga]NODAGA-RGD for imaging ?v?3 integrin expression.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 02-11-2011
Show Abstract
Hide Abstract
A molecular target involved in the angiogenic process is the ?(v)?(3) integrin. It has been demonstrated in preclinical as well as in clinical studies that radiolabelled RGD peptides and positron emission tomography (PET) allow noninvasive monitoring of ?(v)?(3) expression. Here we introduce a (68)Ga-labelled NOTA-conjugated RGD peptide ([(68)Ga]NODAGA-RGD) and compare its imaging properties with [(68)Ga]DOTA-RGD using small animal PET.
Related JoVE Video
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 01-29-2011
Show Abstract
Hide Abstract
(68)Ga-DOTA-Tyr(3)-octreotide positron emission tomography ((68)Ga-DOTA-TOC PET) has proven to be superior to (111)In-DTPA-D-Phe(1)-octreotide ((111)In-octreotide) planar scintigraphy and SPECT imaging in neuroendocrine tumours (NETs). Because of these promising results, we compared the accuracy of (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging with PET in the diagnosis and staging of metastatic phaeochromocytoma and neuroblastoma, referring to radiological imaging as reference standard.
Related JoVE Video
68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: proof of principle.
J. Nucl. Med.
PUBLISHED: 03-31-2010
Show Abstract
Hide Abstract
The diagnosis of invasive pulmonary aspergillosis (IPA) is difficult and lacks specificity and sensitivity. In the pathophysiology of Aspergillus fumigatus, iron plays an essential role as a nutrient during infection. A. fumigatus uses a specific and highly efficient iron uptake mechanism based on iron-complexing ferric ion Fe(III) siderophores, which are a requirement for A. fumigatus virulence. We aimed to evaluate the potential of siderophores radiolabeled with (68)Ga, a positron emitter with complexing properties comparable to those of Fe(III), as a radiopharmaceutical for imaging IPA.
Related JoVE Video
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.
Eur. J. Nucl. Med. Mol. Imaging
PUBLISHED: 03-23-2010
Show Abstract
Hide Abstract
This guidance is meant as a guidance to Part B of the EANM "Guidelines on Good Radiopharmacy Practice (GRPP)" issued by the Radiopharmacy Committee of the EANM (see www.eanm.org ), covering the small-scale "in house" preparation of radiopharmaceuticals which are not kit procedures. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of, for example, PET, therapeutic or other radiopharmaceuticals which are not intended for commercial purposes or distribution.
Related JoVE Video
Novel 99mTc 4 + 1 peptide conjugates: tuning the biodistribution by variation of coligands.
Eur J Med Chem
PUBLISHED: 03-03-2010
Show Abstract
Hide Abstract
A sophisticated coligand strategy is presented for peptide-derived radioconjugates based on (99m)Tc 4 + 1 mixed-ligand complexes. The new pharmacologically active coligands are assessed for (99m)Tc-labeling of the RGD-peptide cyclo(Arg-Gly-Asp-D-Tyr-Lys) which is an established vehicle to target alpha(v)beta(3) integrins playing a crucial part in tumor pathogenesis. Complexes of the general formula [(99m)Tc(NS(3)R)X] were synthesized and evaluated, in which Tc(III) is coordinated by NS(3)R, a derivative of the tetradentate chelator 2,2,2-nitrilotriethanethiol (NS(3)), and by X, a monodentate binding isocyanide bearing the biomolecule. The novel tetradentate chelators (NS(3)R = NS(3)crown, NS(3)en, NS(3)(COOH)(3)) constitute NS(3) with a crown ether, an amine or a tricarboxylic acid as pharmacological modifiers. The isocyanides (X = L2-RGD, L2-Lys) contained the linker isocyanobutanoic acid (L2) coupled to N(6)-Lys of the RGD-peptide and additionally to a single Lys. The lipophilicity (distribution coefficient log D(O)(/W), pH = 7.4) of the RGD-containing radiotracers decreased in the order of the coligands NS(3)crown (-1.7 +/- 0.1), NS(3)en (-2.7 +/- 0.1) and NS(3)(COOH)(3) (-3.3 +/- 0.1). In the same order of the coligands, the biodistribution of the series [(99m)Tc(NS(3)R)(L2-RGD)] in normal rats showed a decrease of hepatobiliary and an increase of urinary excretion. The ratio of specifically to unspecifically uptaken activity (sum of surface bound and internalized activity) in alpha(v)beta(3) integrin-expressing M21 cells was in the range of approximately 4-5 and comparable for all [(99m)Tc(NS(3)R)(L2-RGD)] tracers. The biodistribution of [(99m)Tc(NS(3)en)(L2-RGD)] in nu/nu mice bearing M21 and M21L (control) tumor xenografts exhibited a specific tumor uptake with a low target-background ratio. The metabolic stability of the [(99m)Tc(NS(3)R)(L2-RGD)] tracers in normal rats was high, since 75-87% of the radioactivity in the plasma extract was assigned to the injected radiotracers 60 min after intravenous application in a rat. The hypothetical metabolites [(99m)Tc(NS(3)R)(L2-Lys)] were not found. These results demonstrate a considerable improvement of in vivo properties of (99m)Tc 4 + 1 peptide conjugates and open up the possibility of applying the labeling approach for further radiodiagnostic peptides.
Related JoVE Video
68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
J. Nucl. Med.
PUBLISHED: 08-18-2009
Show Abstract
Hide Abstract
(68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of patients with neuroendocrine tumors. Radionuclide therapy ((90)Y-DOTA-TOC or (177)Lu-DOTA-octreotate) is a choice of treatment that also requires an accurate diagnostic modality for early evaluation of treatment response. Our study compared (68)Ga-DOTA-TOC PET with CT or MRI using the Response Evaluation Criteria in Solid Tumors. Furthermore, standardized uptake values (SUVs) were calculated and compared with treatment outcome.
Related JoVE Video
Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
J. Nucl. Med.
PUBLISHED: 07-17-2009
Show Abstract
Hide Abstract
Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of neuroendocrine tumor. Because detection of distant metastases has a major impact on treatment, early diagnosis of metastatic spread is of great importance. So far, no standard procedure has become established for the early diagnosis of bone metastases from neuroendocrine tumor. We compared the diagnostic value of CT with that of the novel somatostatin analog (68)Ga-1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) in the detection of such metastases.
Related JoVE Video
Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
J. Med. Chem.
PUBLISHED: 07-14-2009
Show Abstract
Hide Abstract
Two cyclized minigastrin analogues for gastrin receptor scintigraphy were synthesized and derivatized with HYNIC at the N-terminus for labeling with 99mTc. Radiolabeling efficiency, stability, cell internalization, and receptor binding on CCK-2 receptor expressing AR42J cells were studied and the biodistribution evaluated in tumor bearing nude mice, including NanoSPECT/CT imaging. Metabolites in urine, liver, and kidneys were analyzed by radio-HPLC. Radiolabeled cyclic MG showed high stability in vitro and receptor mediated uptake in AR42J cells. In the animal tumor model, fast renal clearance and low nonspecific uptake in most organs were observed. A tumor uptake >3% was calculated ex vivo 1 h p.i. for both 99mTc-EDDA-HYNIC-cyclo-MG1 and 99mTc-EDDA-HYNIC-cyclo-MG2. In an imaging study with 99mTc-EDDA-HYNIC-cyclo-MG1, the tumor was clearly visualized. The metabolite analysis indicated rapid enzymatic degradation in vivo.
Related JoVE Video
Radiolabelled RGD peptides and peptidomimetics for tumour targeting.
Front Biosci (Landmark Ed)
PUBLISHED: 03-11-2009
Show Abstract
Hide Abstract
Imaging techniques allowing non-invasive monitoring of tumour angiogenesis have attracted great interest over the last years. The integrin alpha(v)beta3 is overexpressed during tumour spread and metastasis and therefore is an attractive target for monitoring angiogenetic processes. This review summarizes attempts to develop radiolabelled peptides based on the Arg-Gly-Asp (RGD) sequence and related peptidomimetics with high affinity and selectivity for the alpha(v)beta3 integrin for tumour targeting. Most developments were based on cyclic RGD peptides radiolabelled with 18F, 64Cu, 68Ga for PET, 99mTc for SPECT or 177Lu for therapeutic applications. To enable fast elimination from non target tissue and rapid excretion of the radiolabelled peptides pharmacokinetic modifiers such as sugar amino acids have been evaluated. Out of these developments (18F)Galacto-RGD has shown high tumour-to-background ratios preclinically and has been evaluated in a number of clinical studies, showing the possibility for non invasive imaging of alpha(v)beta3 in tumour patients. To improve targeting efficiency multimeric constructs were reported revealing improved targeting properties in preclinical models. These developments still have to be transferred into the clinical setting.
Related JoVE Video
Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Int J Nanomedicine
Show Abstract
Hide Abstract
Liposomes have been proposed to be a means of selectively targeting cancer sites for diagnostic and therapeutic applications. The focus of this work was the evaluation of radiolabeled PEGylated liposomes derivatized with varying amounts of a cyclic arginyl-glycyl-aspartic acid (RGD) peptide. RGD peptides are known to bind to ?(v)?(3) integrin receptors overexpressed during tumor-induced angiogenesis.
Related JoVE Video
Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Eur. J. Nucl. Med. Mol. Imaging
Show Abstract
Hide Abstract
The aim of this study was to evaluate the impact of (68)Ga-labelled DOTA(0)-lanreotide ((68)Ga-DOTA-LAN) on the diagnostic assessment of neuroendocrine tumour (NET) patients with low to moderate uptake on planar somatostatin receptor (SSTR) scintigraphy or (68)Ga-labelled DOTA(0),Tyr(3)-octreotide ((68)Ga-DOTA-TOC) positron emission tomography (PET).
Related JoVE Video
[??Ga]NS?-RGD and [??Ga] Oxo-DO3A-RGD for imaging ?(v)?? integrin expression: synthesis, evaluation, and comparison.
Nucl. Med. Biol.
Show Abstract
Hide Abstract
??Ga-labeled RGD peptides in combination with PET allow non-invasive determination of ?(v)?? integrin expression which is highly increased during tumor-induced angiogenesis. The aim of this study was to synthesize and evaluate two RGD peptides containing alternative chelating systems, namely [??Ga]NS?-RGD-RGD and [??Ga]Oxo-DO3A-RGD and to compare their in vitro and in vivo properties with [??Ga]DOTA- and [??Ga]NODAGA-RGD.
Related JoVE Video
Gallium-68 -- a new opportunity for PET available from a long shelf-life generator - automation and applications.
Curr Radiopharm
Show Abstract
Hide Abstract
(68)Ge/(68)Ga generators have received tremendous attention in the last years based on the success of (68)Ga-labelled Somatostatin analogues for Positron-Emission Tomography (PET), which are today used routinely worldwide. Various commercially available generator types are based on different column matrices including TiO(2), SnO(2) or organic (68)Gechelate coated silica, providing (68)Ga as Ga(3+) in HCl for radiolabeling procedures. These systems can serve as a stable source of (68)Ga for PET applications over periods of more than one year with high yields. A number of methods for post processing of the eluate including fractionation, anion or cation exchange purification have been developed. These methods are particularly important for high specific activity labeling of biomolecules such as peptides ensuring small volumes, low metallic contamination and low (68)Ge breakthrough. These systems have been implemented into fully automated modules allowing generator elution, post processing radiolabeling and formulation, complying with high regulatory demands. Quality aspects regarding the clinical use of (68)Ga for patient applications including limit of (68)Ge content, metal contamination, microbiological safety and radiochemical purity have been addressed. Overall, the establishment of (68)Ge/(68)Ga generator technology together with the development of novel (68)Ga-radiopharmaceuticals make (68)Ga a most promising radionuclide for PET in the years to come.
Related JoVE Video
Microbial challenge tests on nonradioactive TiO2-based 68Ge/68Ga generator columns.
Nucl Med Commun
Show Abstract
Hide Abstract
The aim of this study was to test the survival of microorganisms in eluents used for (68)Ge/(68)Ga generators and for regeneration of nonradioactive (68)Ge/(68)Ga generator columns after high microbial load. Nonradioactive generator columns were loaded with various microorganisms and tested to determine whether the microorganisms were proliferating or surviving in eluates of the columns.
Related JoVE Video
Comparison of ??Ga-DOTATATE and ??Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Eur. J. Nucl. Med. Mol. Imaging
Show Abstract
Hide Abstract
Recent studies have suggested that positron emission tomography (PET) imaging with (68)Ga-labelled DOTA-somatostatin analogues (SST) like octreotide and octreotate is useful in diagnosing neuroendocrine tumours (NETs) and has superior value over both CT and planar and single photon emission computed tomography (SPECT) somatostatin receptor scintigraphy (SRS). The aim of the present study was to evaluate the role of (68)Ga-DOTA-1-NaI(3)-octreotide ((68)Ga-DOTANOC) in patients with SST receptor-expressing tumours and to compare the results of (68)Ga-DOTA-D-Phe(1)-Tyr(3)-octreotate ((68)Ga-DOTATATE) in the same patient population.
Related JoVE Video
Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging.
Eur. J. Nucl. Med. Mol. Imaging
Show Abstract
Hide Abstract
Invasive pulmonary aspergillosis is mainly caused by Aspergillus fumigatus, and is one of the major causes of morbidity and mortality in immunocompromised patients. The mortality associated with invasive pulmonary aspergillosis remains high, mainly due to the difficulties and limitations in diagnosis. We have shown that siderophores can be labelled with (68)Ga and can be used for PET imaging of A. fumigatus infection in rats. Here we report on the further evaluation of the most promising (68)Ga-siderophore candidates, triacetylfusarinine (TAFC) and ferrioxamine E (FOXE).
Related JoVE Video
Feasibility and availability of ??Ga-labelled peptides.
Eur. J. Nucl. Med. Mol. Imaging
Show Abstract
Hide Abstract
(68)Ga has attracted tremendous interest as a radionuclide for PET based on its suitable half-life of 68 min, high positron emission yield and ready availability from (68)Ge/(68)Ga generators, making it independent of cyclotron production. (68)Ga-labelled DOTA-conjugated somatostatin analogues, including DOTA-TOC, DOTA-TATE and DOTA-NOC, have driven the development of technologies to provide such radiopharmaceuticals for clinical applications mainly in the diagnosis of somatostatin receptor-expressing tumours. We summarize the issues determining the feasibility and availability of (68)Ga-labelled peptides, including generator technology, (68)Ga generator eluate postprocessing methods, radiolabelling, automation and peptide developments, and also quality assurance and regulatory aspects. (68)Ge/(68)Ga generators based on SnO(2), TiO(2) or organic matrices are today routinely supplied to nuclear medicine departments, and a variety of automated systems for postprocessing and radiolabelling have been developed. New developments include improved chelators for (68)Ga that could open new ways to utilize this technology. Challenges and limitations in the on-site preparation and use of (68)Ga-labelled peptides outside the marketing authorization track are also discussed.
Related JoVE Video
(68)Ga-Triacetylfusarinine C and (68)Ga-Ferrioxamine E for Aspergillus Infection Imaging: Uptake Specificity in Various Microorganisms.
Mol Imaging Biol
Show Abstract
Hide Abstract
(68)Ga-triacetylfusarinine C ((68)Ga-TAFC) and (68)Ga-ferrioxamine E ((68)Ga-FOXE) showed excellent targeting properties in Aspergillus fumigatus rat infection model. Here, we report on the comparison of specificity towards different microorganisms and human lung cancer cells (H1299).
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.